• Radiation Therapy
      • Treatment Delivery
        • Unity Unity
        • Versa HD Versa HD
        • Harmony Harmony
        • Elekta Infinity Elekta Infinity
        • Elekta Synergy Elekta Synergy
      • Treatment Management
        • Monaco
        • ProKnow
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Leksell Gamma Knife Icon Leksell Gamma Knife Icon
        • Leksell Gamma Knife Perfexion Leksell Gamma Knife Perfexion
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell Gamma Knife Lightning
        • Leksell GammaPlan
    • Oncology Informatics
      • MOSAIQ Plaza
        • Subscribe to better
        • Professional Services
        • Interoperability
      • Elekta Axis Cloud
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Rectum
        • Bladder
        • Gynecology
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
        • Leksell Stereotactic System Leksell Stereotactic System
    • Elekta Care Customer Services
    • Elekta Care Learning
    • Elekta Care Community
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Management
        • Integrity Line
        • Programs
        • Sponsorship and Donation
        • Story
    • Sustainability
      • Sustainability
        • Access to healthcare
        • Business Ethics
        • Global Environment Policy
        • Green Processes
        • People and Human Rights Policy
        • People in Focus
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Management
              • Auditors
              • Articles of Association
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • The share
                  • Financials
                    • Funding
                      • Reports & presentations
                      • Press releases
                      • IR calendar
                      • IR contacts
                  • Newsroom
                    • Newsroom
                      • Press Releases
                      • FOCUS magazine
                      • Events
                      • Image bank
                  • Careers at Elekta
                  • Company update
                  • Reimbursement
                ENSV
                Login
                • Products
                  • Radiation Therapy
                    • Treatment Delivery
                      • Unity
                      • Versa HD
                      • Harmony
                      • Elekta Infinity
                      • Elekta Synergy
                    • Treatment Management
                      • Monaco
                      • ProKnow
                    • Quality Assurance
                      • Machine QA
                      • Patient QA
                  • Stereotactic Radiosurgery
                    • Delivery
                      • Leksell Gamma Knife Icon
                      • Leksell Gamma Knife Perfexion
                    • Treatment Planning
                      • Leksell Gamma Knife Lightning
                      • Leksell GammaPlan
                    • Versa HD
                  • Oncology Informatics
                    • MOSAIQ Plaza
                      • Subscribe to better
                      • Professional Services
                      • Interoperability
                    • Elekta Axis Cloud
                  • Brachytherapy
                    • Elekta Studio
                    • ImagingRing
                    • Venezia
                    • Flexitron
                    • Geneva
                    • Head and Neck
                    • Bronchus and Oesophagus
                    • Breast
                    • Skin
                    • Prostate
                    • Rectum
                    • Bladder
                    • Gynecology
                    • Oncentra Brachy
                  • Neurosurgery
                    • Leksell Vantage Stereotactic System
                    • Leksell Stereotactic System
                • Services
                  • Elekta Care Customer Services
                  • Elekta Care Learning
                  • Elekta Care Community
                • Patients
                  • Brachytherapy Treatment
                  • Gamma Knife Treatment
                  • Radiation Therapy Treatment
                  • Treatment Centers
                • Company
                  • About us
                    • Board of Directors
                    • Code of Conduct
                    • Corporate Citizenship
                    • Executive Management
                    • Integrity Line
                    • Programs
                    • Sponsorship and Donation
                    • Story
                  • Sustainability
                    • Access to healthcare
                    • Business Ethics
                    • Global Environment Policy
                    • Green Processes
                    • People and Human Rights Policy
                    • People in Focus
                  • Corporate Governance
                    • Shareholders’ meetings
                      • Board of Directors
                        • Executive Management
                          • Auditors
                          • Articles of Association
                          • Reports
                        • Investors
                          • Investment case
                            • Outlook
                            • The share
                              • Financials
                                • Funding
                                  • Reports & presentations
                                  • Press releases
                                  • IR calendar
                                  • IR contacts
                                • Newsroom
                                  • Press Releases
                                  • FOCUS magazine
                                  • Events
                                  • Image bank
                                • Careers at Elekta
                                • Company update
                                • Reimbursement
                              • Contact
                              • Medical Affairs
                              • Regulatory Affairs
                              • Suppliers
                                • About Elekta Procurement
                                • Sustainable Sourcing
                                • Performance Management
                                  • Production Part Approval Process
                                  • Supplier Escalation Form
                                  • Non Conformance Management
                                  • Supplier Performance Management
                                  • Obsolescence Management
                                • Compliance Management
                                • Invoicing Process
                                • Elekta T&C
                                • Documents & Training
                                • Our Global Presence
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube

                              Interim report May – January 2012/13

                              March 05, 2013
                              • Order bookings increased 13* percent to SEK 8,080 M (7,186).
                              • Net sales increased 11* percent to SEK 6,608 M (5,929).
                              • Operating result amounted to SEK 873 M (967) excluding non-recurring items of SEK -24 M (107).
                              • Net income amounted to SEK 504 M (687). Earnings per share amounted to SEK 1.31 (1.83) before dilution and SEK 1.30 (1.81) after dilution. In September 2012 a 4:1 share split was conducted. All data per share has been restated pro forma.
                              • Cash flow after investments was SEK 335 M (372).
                              • Exchange rate movements compared to fiscal year 2011/12 are expected to have a negative impact of approximately three percentage points on growth of net sales as well as operating profit for the 2012/13 fiscal year.
                              • On March 1, Elekta launched Versa HD™ - a new revolutionary linear accelerator system designed to significantly improve cancer care for the patients. Featuring high dose delivery and precision beam shaping, Versa HD is designed for improved treatment optimization and higher efficiency.
                              • The outlook has been adjusted due to effects of recent exchange rate volatility, uncertainty in the US and postponed business in the Middle East. Based on current market conditions, net sales is expected to increase by approximately 15 percent in local currency for the 2012/13 fiscal year. Operating profit is expected to increase by more than 15 percent, excluding currency effects.

                              * Compared to last fiscal year based on constant exchange rates.

                              President and CEO comments
                              Demand in Elekta’s markets has been favorable so far this fiscal year. In total, order bookings increased by 13* percent for the first nine months with growth in all regions. In the third quarter order bookings increased by 6* percent.

                              The North American market has lately been more cautious, mainly due to uncertainty about the budget agreement in the US. Elekta’s order bookings was impacted by a decided but not yet implemented reduction in reimbursement levels for Medicare patients receiving treatment from Leksell Gamma Knife®. We provide both linac-based SRS systems and Leksell Gamma Knife® and we remain committed in our pursuit of the best options and effectiveness in treatment of the patients.

                              The order trend in the Asia Pacific region was excellent and Elekta has strengthened its market-leading position. Several countries there are progressing with structural and long-term expansion of cancer care.

                              Orders in Europe were overall in line with expectations. The demand scenario is good in most parts of Europe, where Elekta continues to make solutions available for qualitative and cost-efficient cancer care for an increasing number of patients. However, the political uncertainty in the Middle East region resulted in that business has been postponed.

                              During a well-attended event in Atlanta, US, we recently launched our new linear accelerator system, Versa HDTM. It is a revolutionary system that aims to significantly improve cancer care and quality of life for patients around the world. Versa HDTMhas a unique combination of high dose rates, exceptional resolution, speed and low radiation leakage, all key elements for improving cancer care. The system also offers customized solutions for the major cancer indications, enabling more patient-specific care. The interest and initial response from our customers have been very good.

                              Our long-term development project, aimed at facilitating treatment combined with advanced magnetic resonance (MR) imaging, continues according to plan. The University of Texas MD Anderson Cancer Center in Texas, US, recently joined the consortium of leading clinics contributing to the development of the system together with Elekta.

                              Cash flow after investments amounted to SEK 335 M (372) for the period. Cash conversion amounted to 44 percent for the first nine months. Our aim remains to achieve cash generation in excess of 70 percent for the fiscal year.

                              Net sales for the first nine months increased by 11* percent. In the third quarter net sales was lower compared to the strong comparison quarter last year. In the third quarter previous year, the newly acquired Nucletron contributed strongly to net sales, partly due to their fiscal year ended in December and this effect is estimated to SEK 200 M. We anticipate that in the fourth quarter we will see strong growth in net sales and have a substantial contribution from our Brachytherapy business. Operating profit decreased with SEK 94 M to SEK 873 M, excluding non-recurring items. Operating profit was negatively impacted primarily by the lower net sales from Nucletron, increased investments in R&D as well as exchange-rate fluctuations that had a negative effect of approximately SEK 50 M.

                              We expect a strong fourth quarter. The outlook has been adjusted due to effects of recent exchange rate volatility, uncertainty in the US and postponed business in the Middle East. Based on current market conditions, net sales is expected to increase by approximately 15 percent in local currency for the 2012/13 fiscal year. Operating profit is expected to increase by more than 15 percent excluding currency effects.

                              Exchange rate movements compared to FY 2011/12 are expected to have a negative impact of approximately three percentage points on growth of net sales as well as operating profit for the 2012/13 fiscal year.

                              * Compared to last fiscal year based on constant exchange rates.

                              Tomas Puusepp
                              President and CEO

                              Conference call
                              Elekta will host a telephone conference at 10:00 – 11:00 CET on March 5, with President and CEO Tomas Puusepp and CFO Håkan Bergström.
                              To take part in the conference call, please dial in about 5-10 minutes in advance and use the access code 927781.
                              Swedish dial-in number: +46 (0)8 5052 0110, UK dial-in number: +44 (0)20 7162 0077, US dial-in number: + 1 877 491 0064.
                              The telephone conference will also be broadcasted over the internet (listen only). Please use the link:
                              http://webeventservices.reg.meeting-stream.com/73934_elekta

                              For further information, please contact:

                              Håkan Bergström, CFO, Elekta AB (publ)
                              +46 8 587 25 547, hakan.bergstrom@elekta.com

                              Johan Andersson, Director Investor Relations, Elekta AB (publ)
                              +46 8 587 25 415, johan.anderssonmelbi@elekta.com

                              The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on March 5, 2013.

                              Downloads

                              • The full report
                              • Products
                                • Radiation Therapy
                                • Stereotactic Radiosurgery
                                • Oncology Informatics
                                • Brachytherapy
                                • Neurosurgery
                              • Services
                                • Elekta Care Customer Services
                                • Elekta Care Learning
                                • Elekta Care Community
                              • Patients
                                • Brachytherapy Treatment
                                • Gamma Knife Treatment
                                • Radiation Therapy Treatment
                                • Treatment Centers
                              • Company
                                • About us
                                • Sustainability
                                • Corporate Governance
                                • Investors
                                • Newsroom
                                • Careers at Elekta
                                • Country and regional pages
                                • Digital Product Security
                                • Offices
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube
                              • ©2022 Elekta
                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                              Contact and Support

                              Offices Customer support

                              By clicking the 'Submit' button below you agree to the Elekta Privacy Policy.

                              © 2022 Elekta

                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.